Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 19/20 | 0.49 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26765583 | 0.93 | IRAK4 (0.49) | IRAK4SMPD3 | |
| SCHEMBL26766375 | 0.93 | IRAK4 (0.48) | IRAK4SMPD3 | |
| SCHEMBL26766377 | 0.93 | IRAK4 (0.48) | IRAK4SMPD3 | |
| SCHEMBL26766372 | 0.93 | IRAK4 (0.48) | IRAK4SMPD3 | |
| SCHEMBL25339224 | 0.91 | IRAK4 (0.51) | IRAK4SMPD3 | |
| SCHEMBL26765556 | 0.91 | IRAK4 (0.46) | IRAK4SMPD3 | |
| SCHEMBL29768038 | 0.89 | IRAK4 (0.50) | IRAK4SMPD3 | |
| SCHEMBL25340195 | 0.86 | IRAK4 (0.45) | IRAK4 | |
| SCHEMBL25337834 | 0.84 | IRAK4 (0.48) | IRAK4SMPD3 | |
| SCHEMBL25340916 | 0.84 | IRAK4 (0.49) | IRAK4SMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885SMPD3 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.